NorthWest Biotherapeutics Inc (NWBO)

[reg2015]

Iclight, Question please. You are 100% correct stating the protacall. My confusion is about when a patient, no matter what they received, progresses. that counts as an "event". Yes or No?

So even if whoever "crosses over" they have already "evented" for PFS? Yes or no?

It is not until the trial is un-blinded will we know who received the placebo and who received DCVAX L.

Then we see who crossed over and when and what the giving of the sure treatment did for the patent from the time of actually getting what was originally prepared for them and then what happened to their disease load.

See, I am confused about how the crossover population changes the PFS #? I would think it would effect the OS # if the treatment is efficacious.

Obviously, this is above my pay grade and I just hope and dream that cancer sufferers can someday have hope of their own immune system fighting and destroying ones own cancer. GLTA